BeiGene, Ltd. (ONC)vsRein Therapeutics Inc (RNTX)
ONC
BeiGene, Ltd.
$283.45
+2.81%
HEALTHCARE · Cap: $31.62B
RNTX
Rein Therapeutics Inc
$1.30
+6.56%
HEALTHCARE · Cap: $31.28M
Smart Verdict
WallStSmart Research — data-driven comparison
ONC leads profitability with a 5.4% profit margin vs 0.0%. ONC earns a higher WallStSmart Score of 42/100 (D).
ONC
Hold42
out of 100
Grade: D
RNTX
Avoid19
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-1983.5%
Fair Value
$16.86
Current Price
$283.45
$266.59 premium
Intrinsic value data unavailable for RNTX.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 32.8% year-over-year
Conservative balance sheet, low leverage
No standout strengths identified
Areas to Watch
0.0% earnings growth
ROE of 7.5% — below average capital efficiency
5.4% margin — thin
Premium valuation, high expectations priced in
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Comparative Analysis Report
WallStSmart ResearchBull Case : ONC
The strongest argument for ONC centers on Revenue Growth, Debt/Equity. Revenue growth of 32.8% demonstrates continued momentum.
Bull Case : RNTX
RNTX has a balanced fundamental profile.
Bear Case : ONC
The primary concerns for ONC are EPS Growth, Return on Equity, Profit Margin. A P/E of 111.0x leaves little room for execution misses.
Bear Case : RNTX
The primary concerns for RNTX are Revenue Growth, EPS Growth, Market Cap.
Key Dynamics to Monitor
ONC profiles as a hypergrowth stock while RNTX is a value play — different risk/reward profiles.
RNTX carries more volatility with a beta of 1.54 — expect wider price swings.
ONC is growing revenue faster at 32.8% — sustainability is the question.
ONC generates stronger free cash flow (131M), providing more financial flexibility.
Bottom Line
ONC scores higher overall (42/100 vs 19/100) and 32.8% revenue growth. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
BeiGene, Ltd.
HEALTHCARE · BIOTECHNOLOGY · USA
BeiGene, Ltd., an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company is headquartered in Camana Bay, the Cayman Islands.
Visit Website →Rein Therapeutics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Rein Therapeutics Inc (RNTX) is an innovative biopharmaceutical company committed to advancing next-generation therapies aimed at neurodegenerative disorders. Leveraging its proprietary technology platform that integrates advanced neuroscience with drug development, the company is poised to address critical unmet medical needs through a robust and diversified pipeline. Supported by a team of seasoned industry experts, Rein Therapeutics is strategically located in a rapidly evolving therapeutic landscape, presenting a compelling opportunity for institutional investors seeking to engage with pioneering healthcare innovations.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?